For the quarter ending 2025-09-30, ANVS made $7,607,292 in revenue. -$7,262,658 in net income. Net profit margin of -95.47%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 6,291,171 | 5,161,921 | ||
| General and administrative | 1,143,804 | 1,109,532 | ||
| Total operating expenses | 7,434,975 | 6,271,453 | ||
| Operating loss | -7,434,975 | -6,271,453 | ||
| Interest income | 152,317 | 191,395 | ||
| Change in fair value of warrants (note 7) | 20,000 | -140,000 | ||
| Total other income (expense), net | 172,317 | 51,395 | ||
| Net loss | -7,262,658 | -6,220,058 | ||
| Earnings per share, basic | -0.37 | -0.32 | ||
| Earnings per share, diluted | -0.37 | -0.32 | ||
| Weighted average number of shares outstanding, basic | 19,685,071 | 19,486,231 | ||
| Weighted average number of shares outstanding, diluted | 19,685,071 | 19,486,231 | ||
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)